THE EFFECTS OF RENIN-ANGIOTENSIN SYSTEM INHIBITION ON REGRESSION OF ENCAPSULATING PERITONEAL SCLEROSIS
Articles > Article ยท 2008
Authors: Devrim BOZKURT, Pinar CETIN, Savas SIPAHI, Ender HUR, Hasim NAR, Muhittin ERTILAV, Murat SEZAK, Soner DUMAN
PERITONEAL DIALYSIS INTERNATIONAL, Journal Indexed in SCI Expanded, International, 2008, vol 28
Summary
Background: Encapsulating peritoneal sclerosis (EPS) is a clinical syndrome associated with symptoms of ileus and irreversible sclerosis of both visceral and parietal peritoneum. Peritoneal dialysis (PD) patients rarely develop EPS, a severe life-threatening condition of unknown pathogenesis. Angiotensin II is known to promote fibrosis and inflammation in various tissues. Renin-angiotensin system (RAS) blockade provides advantages in the course of diseases such as hypertension, chronic kidney disease, and proteinuria. We have also previously shown that RAS blockade has beneficial effects on hypertonic (3.86%) PD solution-induced peritoneal alterations. Because it shares the same characteristics as other fibrotic processes, peritoneal fibrosis can benefit from RAS blockade.